Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2010 |
A Phase II Trial of Endocrine Therapy in Combination With OSI-906 (an IGF-1R Inhibitor) and Erlotinib (Tarceva®, an EGFR Inhibitor) in Patients With Hormone-sensitive Metastatic Breast Cancer
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in
human beings show that this drug can make a difference in the way anti-estrogens work in
hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that
helps them live and grow. Studies done in the laboratory show that OSI-906 can make a
difference in the way anti-estrogens work in hormone-sensitive breast cancers.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials